Amorphex has developed a soft non-invasive device, TODDD™ to provide sustained drug delivery to the ocular surface. Comfortably concealed under the eyelid, one TODDD can deliver therapeutic levels of drug 24/7 over many months. Its polymer chemistry can incorporate a wide range of drugs. TODDD provides inherent compliance while avoiding the significant difficulties and side effects associated with eye drop delivery.

Video Pitch

Management Team

President & CEO

Robert F. Thompson

- Former president of two Bausch & Lomb divisions (corporate officer) - 25+ years of global marketing expertise - Extensive new product launch experience - In depth executive management of corporate and start-up ophthalmic product development

Founder, VP Clinical Affairs

Charles E. Leahy, O.D., M.S.

- Practicing clinician - Massachusetts Eye and Ear Infirmary - New product development experience with B&L - Extensive ophthalmic pharmaceutical development clinical testing experience - Instructor in Ophthalmology at Mass. Eye and Ear Infirmary, Harvard Medical School

Founder, VP Science and Technology

Edward J. Ellis, Ph.D.

- Former Sr. VP science & technology at B&L - A founder of Polymer Technology (sold to B&L) - 30+ patents - Inventor and developer of numerous commercialized products ($2+Billion in sales) - Expertise in polymers and plastics